Movement Alert｜KEYMED BIO-B Rises 5.41% in Regular Trading, International Licensing Deal with Aeira Marks Key Milestone

On September 21, KEYMED BIO-B rose 5.41% in regular trading, trading at HK$75.65 per share, with turnover of approximately HK$32.59 million. The rally was primarily driven by continued market recognition of the company's accelerating internationalization strategy and a series of positive catalysts.

On the news front, KEYMED BIO-B recently signed an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd., granting the rights for the registration, launch, and commercialization of its self-developed IL-4Ra monoclonal antibody sipulizumab injection across 18 countries and regions in Southeast Asia, Central Asia, and Hong Kong/Macau. The company will continue to be responsible for the product's manufacturing and supply. This agreement represents a significant milestone in KEYMED BIO-B's global expansion.

The deal comes amid a robust operational backdrop. In the first half of the year, the company reported revenue of RMB 617 million and net profit of RMB 1.218 billion, swinging to profitability year-over-year. Key pipeline catalysts include CM512 obtaining breakthrough therapy designation and meeting all Phase 2 endpoints in chronic rhinosinusitis with nasal polyps, and CMG901 achieving positive Phase 3 topline results in advanced gastric cancer with partner AstraZeneca.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)